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The objective of this study was to determine the objective response rate in patients with platinum-sensitive and platinum-resistant
recurrent ovarian cancer to treatment with trabectedin (Yondelis
s) administered as a 3-h infusion weekly for 3 weeks of a 4-week
cycle. We carried out a multicentre Phase II trial of trabectedin in patients with advanced recurrent ovarian cancer. Trabectedin
(0.58mgm
 2) was administered via a central line, after premedication with dexamethasone, to 147 patients as a 3-h infusion weekly
for 3 weeks followed by 1-week rest. Major eligibility criteria included measurable relapsed advanced ovarian cancer and not more
than two prior platinum-containing regimens. Patients were stratified according to the treatment-free interval (TFI) between having
either platinum-sensitive (X6 months TFI) or platinum-resistant disease (o6 months TFI)/platinum-refractory disease (progression
during first line therapy). In the platinum-sensitive cohort, 62 evaluable patients with measurable disease had an overall response rate
(ORR) of 29.0% (95% CI: 18.2–41.9%) and median progression-free survival (PFS) was 5.1 months (95% CI: 2.8–6.2). Four patients
with measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) criteria had no follow-up scans at the end of
treatment. In the platinum-resistant/refractory cohort, 79 patients were evaluable with an ORR of 6.3% (95% CI: 2.1–14.2%). Median
PFS was 2.0 months (95% CI: 1.7–3.5 months). Two patients with measurable disease per RECIST criteria had no follow-up scans at
the end of treatment. The most frequent (X2% of patients) drug-related treatment-emergent grade 3/4 adverse events were
reversible liver alanine transferase elevation (10%), neutropaenia (8%), nausea, vomiting, and fatigue (5% each). Trabectedin is an
active treatment, with documented responses in patients with platinum sensitive advanced relapsed ovarian cancer, and has a
manageable toxicity profile.
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Ovarian cancer is often diagnosed in advanced stages due to the
absence of overt signs or symptoms in earlier-stage disease, with
poor long-term prognosis and 5-year survival rates o30%
(American Cancer Society, 2005). Standard therapy is cytoreductive
surgery followed by platinum-based chemotherapy. Despite high
initial response rates, relapse and chemo-resistance eventually
occur in the majority of patients with advanced disease (Markman
and Bookman, 2000; Harper, 2002).
The National Institute of Health and Clinical Excellence (NICE)
of United Kingdom guidelines (Technology Appraisal Guidance,
2005) recommend that patients with recurrent ovarian cancer
should be classified by their duration of the response to initial
platinum therapy: those with disease recurrence X12 months after
initial therapy are regarded as platinum-sensitive, whereas those
with recurrence 6 to 412 months after initial therapy are regarded
as partial platinum-sensitive (Gordon et al, 2001). Women who
recur p6 months after initial therapy are considered platinum-
resistant and are less likely to receive further benefit from
platinum. Women with disease progression during initial platinum
therapy are regarded as platinum-refractory and require no further
platinum therapy.
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sFew effective single agents are available for second-line and
subsequent therapy following progression on platinum and
taxanes (Markman and Bookman, 2000; Gordon et al, 2001).
Current single agent chemotherapy options for patients include:
re-treatment with a platinum-based regimen or single agent
pegylated liposomal doxorubicin, topotecan, or gemcitabine,
which have shown response rates in the range of 16–40% (Gordon
et al, 2001; Markman et al, 2001; Garcia et al, 2004; Papadimitriou
et al, 2004; National Comprehensive Cancer Network, 2005; Rose,
2005).
Trabectedin (ET-743, Yondelis
s, PharmaMar, SA, Madrid,
Spain and Johnson & Johnson Pharmaceutical Research &
Development, LLC, Raritan, NJ, USA) is a tris, tetrahydroisoquino-
line alkaloid isolated originally from the marine ascidian
Ecteinascidia turbinate and currently produced synthetically. It
binds to the minor groove of DNA at the N2 position of guanine,
inducing a bend towards the major groove (Pommier et al, 1996;
Zewail-Foote and Hurley, 1999; van Kesteren et al, 2003).
Trabectedin inhibits transcription of heat shock-inducible genes
(Minuzzo et al, 2000) and interacts with the transcription-coupled
nucleotide excision repair (TC-NER) system, resulting in forma-
tion of lethal DNA strands, cell cycle arrest, and apoptosis by a
process that is p53 independent (Erba et al, 2001; Takebayashi
et al, 2001). In vitro, low concentrations (2–80nM) of trabectedin
disrupt progression of human cancer cells through S phase,
resulting in accumulation in late S and G2/M (Martinez et al, 2001;
Mandola et al, 2005). Recent data also suggest that the enzyme poly
ADP-ribose polymerase (PARP) may contribute to the cellular
sensitivity of trabectedin (Mandola et al, 2005).
Trabectedin has shown in vitro cytotoxicity against melanoma,
ovarian, colorectal, breast, brain, and lung cancer cell lines
(Jimeno et al, 1996). Soft-tissue sarcoma cell lines have proven
to be highly sensitive to growth inhibition in picomolar
concentrations (Li et al, 2001). Similarly, growth in human solid
tumour colony-forming assays was inhibited (Izbicka et al, 1998).
Trabectedin also inhibits the development of human tumour
xenografts in mice, including melanoma, ovarian cancer, non-
small cell lung cancer, breast, and renal cell carcinomas, with cures
in some models (Jimeno et al, 1996; Valoti et al, 1998; Hendriks
et al, 1999). Valoti et al, (1998) found trabectedin active against
xenografts, inducing long-lasting tumour regressions both in early
and established tumours. Of note, activity was observed in ovarian
xenograft tumours that are sensitive to Cisplatin as well as those
which are resistant to cisplatin.
In Phase I studies, trabectedin showed activity in patients with
ovarian cancer (Salazar et al, 2006), mesothelioma (Ryan et al,
2001), leiomyosarcoma (Villalona-Calero et al, 2002), melanoma
(Ryan et al, 2001), breast cancer (Taamma et al, 2001), endometrial
carcinoma (McMeekin et al, 2004), liposarcoma (Taamma et al,
2001), osteosarcoma (Taamma et al, 2001), and soft-tissue
sarcomas (Yovine et al, 2004). Doses evaluated included 1- to
72-h infusions administered every 3 weeks, 1-h infusion daily for 5
days every 3 weeks, and a 3-h infusion once weekly for 3 out of 4
weeks (Ryan et al, 2001; Villalona-Calero et al, 2002; Twelves et al,
2003). The once weekly regimen for 3 out of 4 weeks appeared to
provide antitumour activity with the benefit of improved patient
tolerability and convenience of administration. Therefore, the
current protocol was initiated at the time of the onset of initial
Phase II studies.
A Phase II study conducted by the Southern Europe New Drugs
Organization Foundation (SENDO) evaluated the use of trabecte-
din in 59 patients with advanced disease including refractory or
relapsing ovarian cancer following a platinum-taxane regimen
(Sessa et al, 2005). An initial dose of 1.65mgm
 2 (reduced to
1.3mgm
 2) was administered as a 3-h infusion every 3 weeks. An
overall response rate (ORR) of 43.5%, one complete response (CR)
and nine partial responses (PR), was reported in 23 evaluable
platinum-sensitive patients. The duration of the patient who
achieved a CR was 8.7 months. The patients who achieved PR had
a median time to progression (TTP) of 7.9 months, and an
additional nine patients exhibited stable disease (SD). The 28
patients with evaluable platinum resistance yielded an ORR of
7.1%, 2 patients with PR each with a TTP of 4 and 4.6 months.
Stable disease was reported in eight (28.6%) additional patients.
The 1.3mgm
 2 dose was well tolerated with transient increase in
aminotransferases and non-fatal (G3) neutropaenia.
The present Phase II trial evaluated trabectedin as a single agent
administered weekly for 3 of 4 weeks in patients with advanced
relapsed ovarian cancer previously treated with a platinum-based
regimen. This study was initiated when the appropriate schedule
and dosing of trabectedin had not been determined. The primary
objective was to determine the ORR in patients with platinum-
sensitive and -resistant disease. Secondary objectives included
duration of response, TTP, progression-free survival (PFS), overall
survival (OS), and safety.
MATERIALS AND METHODS
Patient population
Eligibility criteria included histologically proven epithelial ovarian
carcinoma, fallopian tube carcinoma, or primary peritoneal
carcinoma (excluding peritoneal mesothelioma) treated with one
to two prior platinum-containing regimens (if the second was
started following a progression-free interval of X6 months after
the first regimen); age X18 years; Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1; at least 1 measurable
lesion according to Response Evaluation Criteria in Solid Tumours
(RECIST) (Therasse et al, 2000) guidelines; adequate haematologic
(haemoglobin 49.0g per 100ml, absolute neutrophil count (ANC)
41500 per ml, platelets X100000 per ml), renal (serum creatini-
nepULN), and hepatic function (total bilirubinpULN, total
alkaline phosphatasepULN (or if4ULN, alkaline phosphatase
liver fraction or 50-nucleotidasepULN), AST and ALTp2.5 
ULN, and albuminX2.5gl
 1). The patient population in this study
included platinum-sensitive, -resistant, and -refractory patients
receiving second or third line therapy.
Exclusion criteria included prior trabectedin exposure; one prior
non-platinum-containing regimen in platinum-sensitive patients
(more specific exclusion added after a protocol amendment); more
than two prior chemotherapy regimens; o4 weeks from radiation
therapy hormonal therapy, biological therapy, any investigational
agent; peripheral neuropathyXgrade 2; history of other neoplastic
disease (unless remission for 45 years); known CNS metastasis or
other serious illness; and pregnant or lactating women or those of
childbearing potential not employing adequate contraception.
The Independent Ethics Committee/Independent Review Board
of each participating site approved the study. All patients gave
written informed consent.
Study design and evaluations
This multicentre, open-label, single-arm Phase II trial enrolled
patients in two prospectively defined cohorts: a platinum-sensitive
cohort, defined as relapse after a disease-free interval X6 months
from the end of the last platinum-based chemotherapy; or a
platinum-resistant cohort, defined as disease progression o6
months from the end of the last platinum-based treatment. A 2-
stage design was used to minimise exposure to dose and schedule
of trabectedin until tolerability and efficacy were established.
Vital signs, haematologic parameters, blood chemistry, liver
panels, and physical examinations were performed at baseline
(within 14 days before administration of first drug dose) and
throughout the study including treatment termination. Disease
evaluations were made per RECIST guidelines (Therasse et al,
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s2000) utilising either CT or MRI. CA 125 levels were measured at
screening, after every two cycles, and at study termination.
Patients without measurable disease, clinical progression, or study
discontinuations without radiology documentation at the end of
the study were considered non-evaluable for response.
Dosage and administration
Trabectedin was diluted in 500ml of saline and administered via a
central venous catheter. This resulted in two patients with tissue
extravasations due to catheter-related malfunctions. A dose of
0.58mgm
 2 was administered once weekly as a 3-h infusion for 3
weeks, on a 28-day cycle. All patients were premedicated with
10mg dexamethasone IV 30min before trabectedin infusion, since
dexamethasone pretreatment has been shown in animal and
clinical studies to ameliorate the hepatotoxic effects of trabectedin
by diminishing hepatocellular exposure to the drug (Puchalski
et al, 2002; Sarah et al, 2003). Treatment was continued as long as
clinical benefit was derived or until disease progression. Trabecte-
din was discontinued after patients received at least two cycles
beyond a confirmed CR (McMeekin et al, 2005).
Dose reductions and discontinuations
A maximum of two dose reductions (from 0.58. to 0.49 then to
0.40mgm
 2) were permitted based on toxicity. Prophylactic use of
haematopoietic colony-stimulating factors was not permitted in
the first cycle. In subsequent cycles, they could be used for
secondary prophylaxis according to institutional and American
Society of Clinical Oncology guidelines (American Society of
Clinical Oncology). Treatment delays up to 3 weeks were permitted
for persistent toxicity; beyond this, therapy was discontinued.
Patients were withdrawn because of serious adverse events, disease
progression, or consent withdrawal.
Response and toxicity assessment
Tumour assessment was performed at baseline, every other
treatment cycle until disease progression, and at the end of
treatment. After completion of the treatment phase, patients were
followed for survival every 3 months until death or a predeter-
mined cutoff date approximately 2 months from last patient
treatment termination. Adverse events were assessed at each
treatment visit, treatment termination, and during follow-up.
Toxicities were graded according to the National Cancer Institute
Common Toxicity Criteria V2.0 (National Cancer Institute).
Statistical methods
Sample size for each group was determined using a Simon 2-stage
design. For the platinum-sensitive group, 23 patients were enrolled
in the first stage. If at least four responders were observed,
approximately 25 additional patients were enrolled until 48
platinum-sensitive patients were evaluable for response per
RECIST guidelines. This design had 80% power to reject a
response rate of 15% at a 5% significance level when the true
response rate was 30%. In the platinum-resistant group, 30
patients were enrolled in the first stage. If at least two responders
were observed, approximately 22 additional patients were enrolled
until 52 platinum-resistant patients were evaluable for response
per RECIST guidelines. This design had 80% power to reject a
response rate of 5% at a 5% significance level when the true
response rate was 15%.
For efficacy results, patients were further classified into
subgroups based on TTP from initial platinum therapy: plati-
num-sensitive recurrence X12 months after initial platinum-based
therapy; partial-platinum-sensitive recurrence 6 to o12 months
after initial therapy; platinum-resistant recurrence p6 months
after initial therapy; platinum-refractory, progression during
initial platinum therapy. For final intent-to-treat efficacy analysis,
response rate, TTP, PFS, OS, the 28 patients whose platinum
sensitivity status on enrolment was unknown on initial review, but
later resolved, were appropriately added back to either the
platinum-sensitive or -resistant/refractory patient populations.
Prognostic factors including baseline ECOG performance status
scores; number of platinum-based lines of therapy before
enrolment; TTP from the start of last dose of chemotherapy,
histology; histology grade; or CA125 levels at baseline were
analysed for correlation with ORR.
Summaries of safety were based on laboratory data and
treatment-emergent adverse events (TEAE), defined as any adverse
event occurring on or after the first dose of trabectedin and within
30 days after the last dose.
RESULTS
Patient characteristics
Between October 2002 and September 2004, a total of 170 patients
were screened for enrolment. Baseline characteristics for treated
patients were similar for the platinum-sensitive and -resistant
cohorts, with the exception of ECOG performance status (Table 1).
Of the screened patients, 147 were part of the intent-to-treat
population (23 patients were screen failures) and 141 were
evaluable for efficacy per RECIST guidelines at the end of study
treatment (Table 2). Nearly, all patients received prior cytoreduc-
tive surgery (98%), and 5% had previous radiotherapy. All patients
had received prior platinum-containing chemotherapy. In the
platinum-sensitive patient cohort, 74% had 1 prior line and 26%
had 2 prior lines. Median time from the last chemotherapy
regimen to the first dose was 11 months. In the platinum-resistant/
refractory patient cohort, 65% had 1 prior line and 35% had 2
prior lines, median time from the last chemotherapy regimen to
the first dose was 4.1 months.
Treatment
The 66 platinum-sensitive patients received 304 cycles with a
median of four cycles per patient (range, 1–11); median treatment
duration was 18.6. weeks (range, 4.0–77); median cumulative dose
was 6.5mgm
 2 (range, 1–15); and median dose intensity was
0.353mgm
 2 per week (range, 0.17–0.44) with a relative dose
intensity of 81.1% (range, 38–102%). For the 81 platinum-
resistant/refractory patients, 284 total cycles were administered
with a median of two cycles (range, 1.0–22.0); treatment duration
was 8.9 weeks (range, 4.0–98.0), median cumulative dose was
3.5mgm
 2 (range, 1.0–37.0), median dose intensity was
0.391mgm
 2 per week (range, 0.14–0.46), and the relative dose
intensity was 90.0% (range, 32–105%).
For the platinum-sensitive patients, 42% had at least one cycle
delay, 45% had at least one dose withheld, and 42% had at least one
dose reduction. In the platinum-resistant/refractory patient cohort,
28% had at least one cycle delay, 20% had at least one dose
withheld, and 23% had at least one dose reduction. Reasons for
dose delays and reductions in both cohorts were divided equally
between liver transaminase elevations and myelosuppression.
Twenty-one of 66 (31.8%) patients in the platinum-sensitive
cohort and 8 of 79 (10.1%) in the platinum-resistant cohort
remained on therapy 46 months.
Efficacy
Efficacy and survival data are shown in Table 3. Both statistical
response targets (for platinum-sensitive and -resistant patients)
were reached in our study. The 62 evaluable patients in the
platinum-sensitive cohort had an ORR of 29.0% (27.3% of the total
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splatinum-sensitive population) (4CR, 14PR) (95% CI: 18.2–
41.9%). Partial platinum-sensitive patients (n¼39) yielded an
ORR of 25.6% (1CR, 9PR); SD in 13 (33.3%); disease control
(CRþPRþSD) in 23 (60.0%); and disease progression in 16 (40%)
patients. The platinum-sensitive subgroup (n¼23) had an ORR of
34.8% (3CR, 5PR); SD in 9 (39.1%).
The 79 evaluable patients in the platinum-resistant/refractory
patient cohort had an ORR of 6.3% (6.2% of the total platinum-
resistant/refractory population) (5PR) (95% CI: 2.1–14.2%). The
platinum-resistant subgroup (n¼42) had an ORR of 4.8% (2PR),
SD in 21 (50.0%), and disease progression in 19 (45.2%) patients.
The platinum-refractory subgroup (n¼37), ORR was 8.1% (3PR),
SD in 15 (40.5%), and disease progression in 19 (51.3%) patients.
Six patients of the total patient population were not evaluable
because of early death, clinical progression, or early discontinua-
tion unrelated to toxicity.
Secondary efficacy end points
Secondary efficacy end points included time to response, duration
of response, PFS, and OS. In the platinum-sensitive cohort, the
partial platinum-sensitive subgroup had a median time to response
of 1.8 months (range, 2–5); median duration of response, 5.2
months (95% CI: 3.7–5.8); and a median PFS of 4.0 months (95%
CI: 1.7–6.1). In the platinum-sensitive subgroup (412 month
treatment-free interval), the median time to response was 1.9
months (range, 2–5); median duration of response was not
estimable (NE) because very few patients had disease progression;
and median PFS was 5.1 months (95% CI: 3.1–6.5) (Table 3).
The platinum-resistant subgroup (including platinum-resistant/
refractory patient cohort) had a median time to response of 2.5
months (range, 2–3); median duration of response, 4.2 months;
and a median PFS of 2.3 months (95% CI: 1.7–4.1). The platinum-
refractory subgroup had median time to response of 5.6 months
(range, 2–12); median duration of response, 11.0 months; and a
median PFS of 1.9 months (95% CI: 1.6–2.6) (Table 3).
In the overall platinum-sensitive cohort, TTP was 5.2 months
(95% CI: 3.1–6.5 months) and PFS was 5.1 months (95% CI: 2.8–
6.2 months). Overall survival was NE because very few patients
have died, with a 1-year survival rate of 55.9%. The overall
platinum-resistant cohort had a TTP of 2.0 months (95% CI: 1.77–
3.5 months), PFS of 2.0 months (95% CI: 1.7–3.5 months), and OS
of 10.7 months with a 1-year survival rate of 24.5% (Table 3).
No statistically significant correlation was noted between the
prognostic factors analysed and ORR, PFS, and OS, which may be
explained, in part, by the small sample size.
The concurrence rate between CA125 response (defined as either
a decrease of at least 50% in value or normalisation, confirmed
Table 1 Demographics and baseline characteristics in treated patients
Platinum
sensitive
Platinum
resistant Total
(N¼66) (N¼81) (N¼147)
Race, n (%)
N 66 81 147
Black 4 (6) 2 (2) 6 (4)
White 61 (92) 76 (94) 137 (93)
Asian 0 1 (1) 1 (1)
Other 1 (2) 2 (2) 3 (2)
Age
N 66 81 147
Category, n (%)
18–o40 3 (5) 2 (2) 5 (3)
40–o60 29 (44) 41 (51) 70 (48)
X60 34 (52) 38 (47) 72 (49)
Mean (s.d.) 60.1 (10.43) 58.3 (9.98) 59.1 (10.19)
Median 60.0 59.0 59.0
Range (36; 83) (33; 83) (33; 83)
Baseline weight in kilograms
N 66 81 147
Mean (s.d.) 71.58 (18.213) 69.15 (13.869) 70.24
(15.955)
Median 68.45 69.00 68.60
Range (36.0; 167.0) (42.3; 121.8) (36.0; 167.0)
Baseline ECOG Score, n (%)
N 66 81 147
0 46 (70) 47 (58) 93 (63)
1 20 (30) 34 (42) 54 (37)
Histology, n (%)
N 66 80 146
Endometrioid 8 (12) 3 (4) 11 (8)
Clear cell carcinoma 2 (3) 5 (6) 7 (5)
Mixed epithelial tumour 1 (2) 2 (3) 3 (2)
Papillary/serous 49 (74) 59 (74) 108 (74)
Transitional carcinoma
(Brenner)
1 (2) 0 1 (1)
Peritoneal carcinoma 1 (2) 2 (3) 3 (2)
Fallopian tube carcinoma 1 (2) 2 (3) 3 (2)
Other 3 (5) 7 (9) 10 (7)
Histology grade, n (%)
N 66 79 145
Grade 1 (well-
differentiated)
1 (2) 3 (4) 4 (3)
Grade 2 (moderately
differentiated
16 (24) 12 (15) 28 (19)
Grade 3 (poorly
differentiated)
44 (67) 56 (71) 100 (69)
Unknown 5 (8) 8 (10) 13 (9)
Previous lines systemic
therapy, n (%)
N 66 81 147
1 Prior platinum line 49 (74) 53 (65) 102 (69)
2 Prior platinum line 17 (26) 28 (35) 45 (31)
Table 2 Patient profile
Platinum
sensitive
Platinum
resistant Total
(N¼66) (N¼81) (N¼147)
Reason for Withdrawal/
Termination n (%) n (%) n (%)
Total no. of subjects enrolled 66 (100) 81 (100) 147 (100)
Treated
Evaluable for efficacy per RECIST
Guidelines
62 (94) 79 (98) 141 (96)
Ongoing 3 (5) 3 (4) 6 (4)
Complete response (confirmed) 3 (5) 0 3 (2)
Adverse event/drug-related 6 (9) 2 (2) 8 (5)
Adverse event/not drug -related 2 (3) 6 (7) 8 (5)
Disease progression 42 (64) 57 (70) 99 (67)
Subject ineligible to continue 0 1 (1) 1 (1)
Subject choice 2 (3) 3 (4) 5 (3)
Other 4 (6) 7 (9) 11 (7)
Not evaluable for efficacy per RECIST
Guidelines
4 (6) 2 (2) 6 (4)
Death 1 (2) 0 1 (1)
Adverse event/drug-related 0 1 (1) 1 (1)
Adverse event/not drug -related 1 (2) 0 1 (1)
Subject choice 2 (3) 1 (1) 3 (2)
Note: percentages calculated with the number of subjects in each group as
denominator.
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safter at least 28 days) and objective response was 80% in platinum-
sensitive patients and 90% in platinum-resistant patients. The
concurrence rate between CA125 response and objective response,
including SD (44 month) patients, was decreased to 77%
in platinum-sensitive patients and 69% in platinum-resistant
patients.
Toxicity
Of the 147 patients treated, 146 (99%) reported at least one
laboratory abnormality (worst CTC grade) while on treatment. A
drug-related grade 3/4 TEAE was reported for 39% of the treated
subjects, and in 14% of cycles of therapy. The most common worst
grade 3/4 laboratory abnormalities reported were elevated ALT
(12%/0%), hyponatraemia (8%/1%), neutropaenia (7%/1%), and
hypoalbuminaemia (7%/0%) (Table 4).
The most common TEAEs causing dose modifications were
elevated ALT (20%), granulocytopaenia (18%), increased alkaline
phosphatase (16%), and infusion site complications (7%). Drug-
related TEAEs that led to discontinuation of treatment were
reported for 11 (7%) patients.
All 147 treated patients were included for safety analysis. Most
commonly reported drug-related grade 3/4 TEAEs occurring in
X2% of evaluable patients were elevated ALT (11%), granulocy-
topaenia (6%), and nausea, vomiting, and fatigue (5% each).
Incidence of alopecia was 9% with no drug-related grade 3/4
events. The most frequently drug-related TEAEs (grades 1–4) were
nausea (67%), vomiting (56%), fatigue (60%), constipation (33%),
abdominal pain (11%), and anorexia (28% each) (Table 5).
Five subjects died during study treatment or within 30 days of
the last dose of the study drug. Disease progression was reported
as the cause of death for two subjects, and death was attributed to
drug-related TEAEs for one subject due to drug-related grade 3
dyspnoea, pulmonary oedema, central chest pain, heart murmur,
bilateral pleural effusion, pulmonary hypertension, and left cardiac
failure reported as the cause of death at Cycle 7. Non-drug-related
TEAEs were reported as grade 4 pelvic haemorrhage for one
subject, and cardiac arrest for one subject, both occurring at
Cycle 2.
DISCUSSION
Trabectedin, a novel marine-derived compound with a unique
mechanism of action, has shown activity against a variety of
Table 3 Efficacy results
Platinum
sensitive
(N¼66) n (%)
Platinum
resistant
(N¼81) n (%)
Partial platinum
sensitive (N¼41) n (%)
TTP¼6t oo12 months
Platinum Sensitive
(N¼25) n (%)
TTP¼X12 months
Overall Best Response
a
Evaluable N¼62 (100) N¼79 (100) N¼39 (100) N¼23 (100)
Complete response 4 (6) 0 1 (3) 3 (13)
Partial response 14 (23) 5 (6) 9 (23) 5 (22)
Stable disease 22 (35) 36 (46) 13 (33) 9 (39)
Not followed by PD 3 (5) 7 (9) 3 (8) 0
Followed by On-treatment PD 15 (24) 25 (32) 8 (21) 7 (30)
Followed by off-treatment PD 4 (6) 4 (5) 2 (5) 2 (9)
Progressive disease 22 (35) 38 (48) 16 (41) 6 (26)
Response rates 18 (29) 5 (6.3) 10 (26) 8 (35)
95% CI (18.2; 41.9) (2.1; 14.2) (13.0; 42.1) (16.4; 57.3)
Progression-free survival (mo)
b
Number of assessed 66 81 41 25
Number of censored 14 (21.2) 10 (12.3) 5 (12.2) 9 (36.0)
Number failed 52 (78.8) 71 (87.7) 36 (87.8) 16 (64.0)
Median (95% CI) 5.1 (2.8; 6.2) 2.0 (1.7; 3.5) 4.0 (1.7, 6.1) 5.1 (3.1; 6.5)
Overall survival (mo)
b
Number of assessed 66 81 41 25
Number of censored 49 (74.2) 37 (45.7) 29 (70.7) 20 (80.0)
Number failed 17 (25.8) 44 (54.3) 12 (29.3) 5 (20.0)
Median (95% CI) — (14.8; —)
c 11.1 (7.3; 13.0) 17.1 (14.8; —)
c — (11.5; —)
c
Note: partial platinum-sensitive: TTP¼6t oo12 months from end of last platinum-based treatment; Platinum-sensitive: TTPX12 months from end of last platinum-based
treatment.
aAll evaluable patients.
bBased on Kaplan–Meier product limit estimates.
c(—) Some medians, and lower and upper limits of confidence intervals not estimable.
Table 4 Worst on-treatment
a grade 1–4 laboratory abnormalities
Lab type
b
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
Haematology
Neutrophils 30 (21) 34 (23) 10 (7) 2 (1)
Haemoglobin 84 (58) 30 (21) 4 (3) 0
Platelets 18 (12) 4 (3) 4 (3) 0
Chemistry
Hypoalbuminemia 38 (26) 37 (25) 10 (7) 0
Alk phos 44 (30) 4 (3) 3 (2) 0
AST (SGOT) 79 (54) 19 (13) 4 (3) 0
ALT (SGPT) 59 (40) 42 (29) 18 (12) 0
Bilirubin 8 (5) 4 (3) 0 0
Creatinine 21 (14) 0 0 1 (1)
Creatine Kinase 13 (9) 7 (5) 4 (3) 1 (1)
Hyperglycaemia 84 (58) 31 (21) 7 (5) 2 (1)
Hypoglycaemia 5 (3) 1 (1) 2 (1) 0
Hyperkalemia 8 (5) 2 (1) 2 (1) 0
Hypokalemia 43 (29) 0 6 (4) 0
Hypernatremia 13 (9) 0 0 0
Hyponatremia 46 (32) 0 11 (8) 1 (1)
aWorst grade between the first trabectedin dose and 30 days after the last
trabectedin dose.
bFor each lab test, n¼146/147 treated patients for whom post-
baseline lab data are available except for creatine kinase, hyperglycaemia, and
hypoglycaemia in which cases n¼145/147.
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spreclinical solid tumour models. In a similar Phase II trial of
trabectedin administered every 3 weeks in advanced ovarian
cancer Sessa et al (2005) showed promising results with limited
toxicities. Confirmation of these early results has been seen in the
recently completed every 3 week regimen two arm randomised ET-
743:B-026 study (Del Campo et al, 2006; McMeekin et al, 2007).
The results of the present study and those reported by Sessa et al
(2005), Del Campo et al (2006), and McMeekin et al (2007)
demonstrate the effectiveness of trabectedin as a single agent in the
platinum-sensitive patient population with respect to ORR and
disease stabilisation. The most common TEAE in the three studies
was a self-limiting reversible elevation in liver enzymes, with non-
cumulative myelosuppression being a secondary common adverse
event.
The efficacy results seen in all platinum-sensitive patients
treated every 3 weeks with trabectedin in the SENDO study (Sessa
et al, 2005) showed a response rate of 43.5% (95% CI: 23–65%)
with TTP of 7.9 months (95% CI: 7.5–14.1 months). Similarly, the
ET-743:B-026 study (Del Campo et al, 2006) showed a response
rate of 37.4% (95% CI: 28.2–47.3%) with TTP of 6.8 months
(95% CI: 5.5–7.4 months). These results trend favourably vs the
response rate of 29% (95% CI: 18.2–41.9%) and TTP of 5.2 months
(95% CI: 3.1–6.5 months) seen in this weekly trabectedin-treated
schedule. However, differences in patient numbers as well as
number of prior treatment regimens could contribute to the
efficacy variations between the three studies.
In the case of platinum-resistant/refractory disease, response
rates were low in this weekly schedule study (6.3% (95% CI: 2.1–
14.2%), and less than that seen with the every 3 week trabectedin
schedule (Sessa et al, 2005; Del Campo et al, 2006; McMeekin et al,
2007) where responses seen were 7% in all patients, and 14.3%
(95% CI: 4.0–32.7%) in patients with one prior platinum-based
regimen. The reduction in response observed in this study
compared to the every 3 week data could be related to the
inclusion of a higher percentage of third line and refractory
patients in our study. The small but consistent number of durable
responses seen in all three phase II trabectedin studies suggests
that trabectedin could be combined with another active agent in
this difficult to treat chemo-resistant patient population.
In contrast to the response rates, a more interesting finding in
our study was the duration of response 5.2 months in platinum-
sensitive and 4.2 months in platinum-resistant/refractory patient
cohorts. The progression-free rate at 6 months was 44 and 11% for
the platinum-sensitive and -resistant/refractory groups, respectively.
Trabectedin toxicity was manageable in this study, with only 7%
of the patients discontinuing therapy due to a drug-related TEAE.
Study related, regardless of association with drug, nausea (79%)
and vomiting (56%) were common, although these were generally
not severe (mostly grade 1 or 2) and did not limit therapy. Study
related, regardless of association with drug, fatigue was reported in
70% of patients; however, the incidence of grade 3 (7%) or 4 (0%)
fatigue was minimal. Grade 3 and 4 granulocytopaenia occurred
much less frequently in the current trial (6%) compared with the
Sessa trial (41%) (Sessa et al, 2005). The most common drug-
related TEAE was dose- and schedule-dependent, self-limiting
transaminitis (elevated, ALT 20%), which generally peaked by day
4 or 5 and returned to baseline by day 14.
In summary, trabectedin given as a single agent once weekly for
3 of 4 weeks is effective for the treatment of advanced relapsed
ovarian cancer in the platinum-sensitive patient population.
Responses in the heavily pretreated resistant/refractory patient
population were low in both schedules (every week vs every 3
weeks). Myelosuppression appeared to be less in weekly schedule
(6% vs 18%), whereas dose reductions and dose delays due to acute
transaminitis was 42% in the weekly regimen, which is greater than
the 34% reported in the every 3 week regimen (Sessa et al, 2005).
Further studies in combination with effective and potentially
synergistic agents in this patient population are ongoing. The
chronicity of recurrent ovarian cancer suggests the development of
more non-cross-resistant drug regimens for on-going palliative
treatment. The reported results on tolerability, clinical efficacy,
and durability demonstrate the potential usefulness of trabectedin
as a novel single agent in advanced platinum-sensitive ovarian
cancer in providing an alternative to existing single agents or
combination treatments for ovarian cancer.
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